Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free INNV Stock Alerts

InnovAge (INNV) Competitors

InnovAge logo
$7.96 -0.21 (-2.57%)
Closing price 04:00 PM Eastern
Extended Trading
$7.94 -0.02 (-0.23%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

INNV vs. SHC, OPCH, BLLN, PRVA, and LFST

Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include Sotera Health (SHC), Option Care Health (OPCH), Billiontoone (BLLN), Privia Health Group (PRVA), and LifeStance Health Group (LFST). These companies are all part of the "healthcare" industry.

How does InnovAge compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Sotera Health has higher revenue and earnings than InnovAge. Sotera Health is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sotera Health$1.16B3.76$77.94M$0.2756.78
InnovAge$915.37M1.18-$30.31M$0.05159.20

91.0% of Sotera Health shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by insiders. Comparatively, 1.0% of InnovAge shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sotera Health presently has a consensus price target of $20.67, indicating a potential upside of 34.81%. InnovAge has a consensus price target of $7.00, indicating a potential downside of 12.06%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts plainly believe Sotera Health is more favorable than InnovAge.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sotera Health
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70
InnovAge
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, Sotera Health had 8 more articles in the media than InnovAge. MarketBeat recorded 15 mentions for Sotera Health and 7 mentions for InnovAge. Sotera Health's average media sentiment score of 0.75 beat InnovAge's score of 0.65 indicating that Sotera Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sotera Health
1 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
InnovAge
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sotera Health has a net margin of 6.70% compared to InnovAge's net margin of 0.71%. Sotera Health's return on equity of 42.38% beat InnovAge's return on equity.

Company Net Margins Return on Equity Return on Assets
Sotera Health6.70% 42.38% 6.91%
InnovAge 0.71%2.60%1.23%

Sotera Health has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

Summary

Sotera Health beats InnovAge on 15 of the 16 factors compared between the two stocks.

How does InnovAge compare to Option Care Health?

InnovAge (NASDAQ:INNV) and Option Care Health (NASDAQ:OPCH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

InnovAge has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Option Care Health has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

12.3% of InnovAge shares are held by institutional investors. Comparatively, 98.1% of Option Care Health shares are held by institutional investors. 1.0% of InnovAge shares are held by insiders. Comparatively, 1.7% of Option Care Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Option Care Health has higher revenue and earnings than InnovAge. Option Care Health is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovAge$915.37M1.18-$30.31M$0.05159.20
Option Care Health$5.67B0.59$207.59M$1.2916.51

In the previous week, Option Care Health had 32 more articles in the media than InnovAge. MarketBeat recorded 39 mentions for Option Care Health and 7 mentions for InnovAge. Option Care Health's average media sentiment score of 0.80 beat InnovAge's score of 0.65 indicating that Option Care Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InnovAge
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Option Care Health
18 Very Positive mention(s)
8 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

InnovAge presently has a consensus target price of $7.00, suggesting a potential downside of 12.06%. Option Care Health has a consensus target price of $32.08, suggesting a potential upside of 50.63%. Given Option Care Health's stronger consensus rating and higher probable upside, analysts plainly believe Option Care Health is more favorable than InnovAge.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InnovAge
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Option Care Health
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83

Option Care Health has a net margin of 3.64% compared to InnovAge's net margin of 0.71%. Option Care Health's return on equity of 18.17% beat InnovAge's return on equity.

Company Net Margins Return on Equity Return on Assets
InnovAge0.71% 2.60% 1.23%
Option Care Health 3.64%18.17%7.16%

Summary

Option Care Health beats InnovAge on 15 of the 17 factors compared between the two stocks.

How does InnovAge compare to Billiontoone?

InnovAge (NASDAQ:INNV) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

InnovAge has a net margin of 0.71% compared to Billiontoone's net margin of 0.00%. InnovAge's return on equity of 2.60% beat Billiontoone's return on equity.

Company Net Margins Return on Equity Return on Assets
InnovAge0.71% 2.60% 1.23%
Billiontoone N/A N/A N/A

InnovAge presently has a consensus target price of $7.00, suggesting a potential downside of 12.06%. Billiontoone has a consensus target price of $126.71, suggesting a potential upside of 58.52%. Given Billiontoone's stronger consensus rating and higher probable upside, analysts plainly believe Billiontoone is more favorable than InnovAge.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InnovAge
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Billiontoone
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

12.3% of InnovAge shares are held by institutional investors. 1.0% of InnovAge shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Billiontoone has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovAge$915.37M1.18-$30.31M$0.05159.20
Billiontoone$305.11M12.04$7.45M$0.21380.64

In the previous week, Billiontoone had 1 more articles in the media than InnovAge. MarketBeat recorded 8 mentions for Billiontoone and 7 mentions for InnovAge. Billiontoone's average media sentiment score of 0.76 beat InnovAge's score of 0.65 indicating that Billiontoone is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InnovAge
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Billiontoone
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Billiontoone beats InnovAge on 9 of the 15 factors compared between the two stocks.

How does InnovAge compare to Privia Health Group?

Privia Health Group (NASDAQ:PRVA) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Privia Health Group has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.

Privia Health Group has higher revenue and earnings than InnovAge. Privia Health Group is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Privia Health Group$2.12B1.44$22.92M$0.17142.88
InnovAge$915.37M1.18-$30.31M$0.05159.20

In the previous week, Privia Health Group had 1 more articles in the media than InnovAge. MarketBeat recorded 8 mentions for Privia Health Group and 7 mentions for InnovAge. InnovAge's average media sentiment score of 0.65 beat Privia Health Group's score of 0.16 indicating that InnovAge is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Privia Health Group
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
InnovAge
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

94.5% of Privia Health Group shares are held by institutional investors. Comparatively, 12.3% of InnovAge shares are held by institutional investors. 5.7% of Privia Health Group shares are held by insiders. Comparatively, 1.0% of InnovAge shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Privia Health Group has a net margin of 1.08% compared to InnovAge's net margin of 0.71%. Privia Health Group's return on equity of 3.06% beat InnovAge's return on equity.

Company Net Margins Return on Equity Return on Assets
Privia Health Group1.08% 3.06% 1.77%
InnovAge 0.71%2.60%1.23%

Privia Health Group presently has a consensus price target of $31.31, suggesting a potential upside of 28.89%. InnovAge has a consensus price target of $7.00, suggesting a potential downside of 12.06%. Given Privia Health Group's stronger consensus rating and higher probable upside, research analysts clearly believe Privia Health Group is more favorable than InnovAge.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Privia Health Group
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.79
InnovAge
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Privia Health Group beats InnovAge on 14 of the 16 factors compared between the two stocks.

How does InnovAge compare to LifeStance Health Group?

LifeStance Health Group (NASDAQ:LFST) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

LifeStance Health Group has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

InnovAge has a net margin of 0.71% compared to LifeStance Health Group's net margin of 0.68%. InnovAge's return on equity of 2.60% beat LifeStance Health Group's return on equity.

Company Net Margins Return on Equity Return on Assets
LifeStance Health Group0.68% 0.65% 0.45%
InnovAge 0.71%2.60%1.23%

LifeStance Health Group has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeStance Health Group$1.42B2.00$9.66M$0.02367.75
InnovAge$915.37M1.18-$30.31M$0.05159.20

85.5% of LifeStance Health Group shares are held by institutional investors. Comparatively, 12.3% of InnovAge shares are held by institutional investors. 6.6% of LifeStance Health Group shares are held by company insiders. Comparatively, 1.0% of InnovAge shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LifeStance Health Group presently has a consensus price target of $9.83, suggesting a potential upside of 33.70%. InnovAge has a consensus price target of $7.00, suggesting a potential downside of 12.06%. Given LifeStance Health Group's stronger consensus rating and higher probable upside, equities analysts clearly believe LifeStance Health Group is more favorable than InnovAge.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LifeStance Health Group
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.11
InnovAge
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, InnovAge had 2 more articles in the media than LifeStance Health Group. MarketBeat recorded 7 mentions for InnovAge and 5 mentions for LifeStance Health Group. LifeStance Health Group's average media sentiment score of 0.80 beat InnovAge's score of 0.65 indicating that LifeStance Health Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LifeStance Health Group
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
InnovAge
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

LifeStance Health Group beats InnovAge on 12 of the 17 factors compared between the two stocks.

Get InnovAge News Delivered to You Automatically

Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INNV vs. The Competition

Export
MetricInnovAgeMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$1.08B$8.11B$6.25B$11.87B
Dividend YieldN/A2.18%2.73%5.21%
P/E Ratio159.2324.8429.0428.48
Price / Sales1.1817.51476.4860.89
Price / CashN/A13.2327.6236.52
Price / Book4.524.949.676.67
Net Income-$30.31M$183.43M$3.55B$332.64M
7 Day Performance-3.75%0.20%1.70%2.01%
1 Month Performance4.60%5.27%5.62%9.19%
1 Year Performance175.43%0.38%34.42%39.59%

InnovAge Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INNV
InnovAge
1.4637 of 5 stars		$7.96
-2.6%		$7.00
-12.1%		N/A$1.08B$915.37M159.232,440
SHC
Sotera Health
3.3783 of 5 stars		$15.54
-1.7%		$20.14
+29.6%		N/A$4.43B$1.16B57.563,000
OPCH
Option Care Health
4.8733 of 5 stars		$27.77
-0.6%		$37.27
+34.2%		N/A$4.36B$5.65B21.708,266
BLLN
Billiontoone
N/A$78.23
-4.3%		$126.71
+62.0%		N/A$3.60B$305.11M372.52620
PRVA
Privia Health Group
4.065 of 5 stars		$24.84
+1.8%		$31.31
+26.0%		N/A$3.12B$2.12B146.121,226

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:INNV) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel